Article ID Journal Published Year Pages File Type
8785045 Advances in Radiation Oncology 2016 8 Pages PDF
Abstract
For patients with HN MCC, omission of PORT was associated with a significantly higher risk of local recurrence even among those patients with the lowest-risk tumors (i.e., Stage IA without immune suppression). Thus, it is important to weigh the benefits of PORT against the side effect profile on a case-specific basis for each patient.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , , , ,